Papillary thyroid carcinoma: Demographics, treatment, and outcome in eleven pediatric patients treated at a single institution
โ Scribed by Kuefer, Martin U.; Moinuddin, Mohammed; Heideman, Richard L.; Lustig, Robert H.; Rose, Susan R.; Burstein, Stephen; VanMiddlesworth, Lester; Fleming, Irvin; Jenkins, Jesse J.; Shearer, Patricia D.
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 377 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
โฆ Synopsis
We describe 11 cases (8 females, 3 males) of papillary thyroid carcinoma in children treated at St. Jude Children's Research Hospital over a 33-year period, and review the literature. Ages ranged from 7-25 years (median, 16 years). Six patients had primary papillary thyroid carcinoma. Five patients had secondary papillary thyroid carcinoma after treatment of Hodgkin's disease (n = 2), acute lymphoblastic leukemia (n = 2), and neuroblastoma (n = 1) with chemotherapy and cervical radiation. The typical presentation was either cervical lymphadenopathy or a thyroid mass of short duration. Treatment consisted of thyroidectomy, cervical lymph node dissection, and postoperative thyroid hormone replacement (n = 1), parathyroid reimplantation (n = 1), 131I ablation (n = 4), external-beam irradiation (n = 1), and chemotherapy with doxorubicin (n = 1) or carboplatin and topotecan (n = 1). Nine patients are alive without evidence of disease 3.0-22.4 years from diagnosis. One patient has persistent but stable disease 17.3 years after diagnosis. One patient relapsed with metastatic lung disease 0.3 years after the initial diagnosis. He continues to do well after a brief but unsustained complete radiographic remission of disease to combination chemotherapy with carboplatin and topotecan. Our review supports excellent long-term outcome for primary or secondary papillary thyroid carcinoma in pediatric patients although complications may require close follow-up in a multidisciplinary setting.
๐ SIMILAR VOLUMES
Heparin-induced thrombocytopenia with thrombosis (HITT) can lead to serious morbidity and may be potentially fatal. We reviewed our experience with this entity over a 4-year period, to determine the following: 1) incidence and type of thrombosis in patients with heparin-induced thrombocytopenia (HIT
Cardiac events include angina, myocardial infarction, coronary angioplasty, coronary artery bypass grafting, and valvular surgery. b Miscellaneous events include trauma, carcinoma of the stomach, carcinoma of the prostate, cirrhosis of liver, renal failure, and scleroderma.